{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:17:27Z","timestamp":1761513447928,"version":"build-2065373602"},"reference-count":19,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2014,6,1]],"date-time":"2014-06-01T00:00:00Z","timestamp":1401580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,6,1]],"date-time":"2014-06-01T00:00:00Z","timestamp":1401580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinical-breast-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1016\/j.clbc.2013.12.003","type":"journal-article","created":{"date-parts":[[2014,1,3]],"date-time":"2014-01-03T18:17:56Z","timestamp":1388773076000},"page":"161-168","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Phase II Multicenter Study of Docetaxel and Bevacizumab With or Without Trastuzumab as First-Line Treatment for Patients With Metastatic Breast Cancer"],"prefix":"10.1016","volume":"14","author":[{"given":"Lee S.","family":"Schwartzberg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suprith","family":"Badarinath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark R.","family":"Keaton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barrett H.","family":"Childs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clbc.2013.12.003_bib1","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/nature04483","article-title":"Angiogenesis as a therapeutic target","volume":"438","author":"Ferrara","year":"2005","journal-title":"Nature"},{"issue":"suppl 3","key":"10.1016\/j.clbc.2013.12.003_bib2","first-page":"5","article-title":"A\u00a0review of the efficacy and safety of docetaxel as monotherapy in metastatic breast cancer","volume":"26","author":"Crown","year":"1999","journal-title":"Semin Oncol"},{"key":"10.1016\/j.clbc.2013.12.003_bib3","series-title":"Breast Cancer Management: Applications of Clinical and Translational Evidence to Subject Care","first-page":"63","article-title":"Taxanes: paclitaxel and docetaxel","author":"Nabholtz","year":"2000"},{"key":"10.1016\/j.clbc.2013.12.003_bib4","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1200\/JCO.2011.35.7376","article-title":"First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase III study","volume":"30","author":"Bergh","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clbc.2013.12.003_bib5","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s00432-011-1091-0","article-title":"Meta-analysis of phase III trials of docetaxel alone or in combination with chemotherapy in metastatic breast cancer","volume":"138","author":"Belfiglio","year":"2012","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"key":"10.1016\/j.clbc.2013.12.003_bib6","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1159\/000320640","article-title":"Prospective multicenter randomized phase III study of weekly versus standard docetaxel (D2) for first-line treatment of metastatic breast cancer","volume":"79","author":"Stemmler","year":"2010","journal-title":"Oncology"},{"key":"10.1016\/j.clbc.2013.12.003_bib7","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa1113216","article-title":"Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer","volume":"366","author":"Baselga","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clbc.2013.12.003_bib8","doi-asserted-by":"crossref","first-page":"4963","DOI":"10.1200\/JCO.2005.05.0294","article-title":"Phase III trial comparing three doses of docetaxel for second-line treatment of advanced breast cancer","volume":"24","author":"Harvey","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clbc.2013.12.003_bib9","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.bbrc.2005.05.132","article-title":"Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy","volume":"333","author":"Ferrara","year":"2005","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.clbc.2013.12.003_bib10","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1200\/JCO.2008.21.6457","article-title":"Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer","volume":"28","author":"Miles","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clbc.2013.12.003_bib11","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1056\/NEJMoa072113","article-title":"Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer","volume":"357","author":"Miller","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clbc.2013.12.003_bib12","doi-asserted-by":"crossref","first-page":"4966","DOI":"10.1200\/JCO.2008.21.6630","article-title":"Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer","volume":"27","author":"Gray","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clbc.2013.12.003_bib13","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1093\/annonc\/mdt276","article-title":"First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patients","volume":"24","author":"Miles","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clbc.2013.12.003_bib14","first-page":"417673","article-title":"Bevacizumab and breast cancer: a meta-analysis of first-line phase III studies and a critical reappraisal of available evidence","volume":"2012","author":"Rossari","year":"2012","journal-title":"J\u00a0Oncol"},{"key":"10.1016\/j.clbc.2013.12.003_bib15","doi-asserted-by":"crossref","first-page":"307","DOI":"10.3816\/CBC.2010.n.040","article-title":"A\u00a0phase II trial of docetaxel with bevacizumab as first-line therapy for HER2-negative metastatic breast cancer (TORI B01)","volume":"10","author":"Hurvitz","year":"2010","journal-title":"Clin Breast Cancer"},{"issue":"suppl 3","key":"10.1016\/j.clbc.2013.12.003_bib16","article-title":"First results of AVEREL, a randomized phase III trial to evaluate bevacizumab (BEV) in combination with trastuzumab (H)\u00a0+ docetaxel (DOC) as first-line therapy for HER2-positive locally recurrent\/metastatic breast cancer (LR\/mBC)","volume":"71","author":"Gianni","year":"2011","journal-title":"Cancer Res"},{"key":"10.1016\/j.clbc.2013.12.003_bib17","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clbc.2013.12.003_bib18","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1200\/JCO.2012.46.2762","article-title":"Markers of response for the antiangiogenic agent bevacizumab","volume":"31","author":"Lambrechts","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 2","key":"10.1016\/j.clbc.2013.12.003_bib19","article-title":"Plasma biomarker analyses in the AVADO phase III randomized study of first-line bevacizumab\u00a0+ docetaxel in patients with human epidermal growth factor receptor (HER) 2-negative metastatic breast cancer","volume":"70","author":"Miles","year":"2010","journal-title":"Cancer Res"}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152682091300308X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152682091300308X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:12:26Z","timestamp":1761513146000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S152682091300308X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6]]},"references-count":19,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["S152682091300308X"],"URL":"https:\/\/doi.org\/10.1016\/j.clbc.2013.12.003","relation":{},"ISSN":["1526-8209"],"issn-type":[{"type":"print","value":"1526-8209"}],"subject":[],"published":{"date-parts":[[2014,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase II Multicenter Study of Docetaxel and Bevacizumab With or Without Trastuzumab as First-Line Treatment for Patients With Metastatic Breast Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clbc.2013.12.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}